<DOC>
	<DOCNO>NCT00770588</DOCNO>
	<brief_summary>This double blind , multicentre , randomize , placebo-controlled study . The eligible patient randomize receive gefitinib placebo 1:1 ratio . This study recruit 296 male female , histologically cytologically diagnose locally advanced metastatic NSCLC patient World Health Organization ( WHO ) Performance Status ( PS ) 0-2 . Patients must complete 4 cycle platinum base first line doublet chemotherapy without experience disease progression unacceptable toxicity . The chemotherapy shall give every 3 week , include cisplatin carboplatin , combine one following : gemcitabine , paclitaxel , docetaxel , vinorelbine .</brief_summary>
	<brief_title>Assess Efficacy , Safety Tolerability Gefitinib ( IressaÂ® 250mg ) Maintenance Therapy Locally Advanced Metastatic ( Stage IIIB/IV ) Non Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically cytologically confirm locally advance metastatic ( stage=IIIB/IV ) nonsmall cell lung cancer ( NSCLC ) front line chemotherapy . Note : sputum cytology alone acceptable Patients complete 4 cycle first line platinum contain doublet chemotherapy without progression intolerable toxicity . Patients PR SD study entry need one measurable lesion accord RECIST criterion . The study treatment start least 3 week ( 21 day ) 6 week ( 42 day ) since last dose chemotherapy , within 4 week ( 28 day ) since last tumour assessment . Prior exposure monoclonal antibody small molecule inhibitor EGFR receptor . ( e.g . gefitinib , erlotinib , C225 ) Patients previously diagnose treat CNS metastases spinal cord compression may consider clinically stable discontinue steroid therapy least 4 week prior first dose study medication . Any evidence clinically active interstitial lung disease ( patient chronic , stable , radiographic change asymptomatic need exclude ) Known biomarker status one following : Tumour EGFR gene copy number , tumour EGFR gene mutation status , tumour EGFR protein expression .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>non-small cell lung cancer ( NSCLC )</keyword>
	<keyword>Gefitinib</keyword>
</DOC>